GPH101 for sickle cell disease granted U.S. FDA Fast Track Designation; dosing of first patient in Phase 1/2 CEDAR clinical...
Finance
NeuBase Therapeutics, Inc.Investigational New Drug (IND)-enabling studies continue to generate promising data that support further development of the company’s lead...
Conference call begins at 2:00 p.m. Pacific time todayPLEASANTON, Calif., May 12, 2022 /PRNewswire/ -- Today, Movano Inc. (NASDAQ: MOVE),...